Blood Stream Infection Testing Market Report 2026

Blood Stream Infection Testing Market Overview

• Blood Stream Infection Testing market size has reached to $8.49 billion in 2025 • Expected to grow to $14.71 billion in 2030 at a compound annual growth rate (CAGR) of 11.6% • Growth Driver: Rising Infectious Disease Rates Drive Growth In Bloodstream Infection Testing Market • Market Trend: Next-Generation Molecular Approaches For Faster Infection Assessment • North America was the largest region in 2025.

What Is Covered Under Blood Stream Infection Testing Market?

Blood stream infection testing involves diagnostic procedures to detect and identify pathogens in the blood, such as bacteria, fungi, or viruses, that cause infections. It typically includes blood cultures and molecular assays to determine the specific microorganism responsible. Accurate and timely testing is crucial for effective treatment and management of sepsis and other serious infections. The main product types in blood stream infection testing are instruments, reagents and consumables, and software and services. Instruments in blood stream infection testing refer to the specialized devices and equipment used to detect and analyze pathogens in blood samples, enabling accurate diagnosis and monitoring of infections. Bloodstream infection testing is conducted on sample types such as whole blood and blood culture, utilizing technologies such as polymerase chain reaction (PCR), mass spectroscopy, in situ hybridization, and others. The end-users of this testing are hospitals and diagnostic centers, laboratory service providers, academic and research institutes, and others.

What Is The Blood Stream Infection Testing Market Growth Forecast?

The blood stream infection testing market size is expected to see rapid growth in the next few years. It will grow to $14.71 billion in 2030 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to increasing demand for rapid diagnostic turnaround times, rising adoption of molecular diagnostics in hospitals, expansion of personalized infection management, growing investments in advanced laboratory infrastructure, increasing integration of ai-assisted diagnostic tools. Major trends in the forecast period include increasing adoption of rapid molecular diagnostic assays, rising use of automated blood culture systems, growing integration of antimicrobial susceptibility testing, expansion of multiplex pathogen detection panels, enhanced focus on early sepsis diagnosis.

Global Blood Stream Infection Testing Market Segmentation

1) By Product Type: Instruments, Reagents And Consumables, Software And Services 2) By Sample Type: Whole Blood, Blood Culture 3) By Technology: Polymerase Chain Reaction (PCR), Mass Spectroscopy, In Situ Hybridization, Other Technologies 4) By End-User: Hospitals And Diagnostic Centers, Laboratory Service Providers, Academic And Research Institutes, Other End-Users Subsegments: 1) By Instruments: Blood Culture Systems, Automated Microbial Identification Systems, Molecular Diagnostic Instruments 2) By Reagents And Consumables: Blood Culture Media, Antimicrobial Susceptibility Testing Reagents, Nucleic Acid Extraction Kits 3) By Software And Services: Laboratory Information Management Systems (LIMS), Data Analysis Software, Maintenance And Support Services

What Is The Driver Of The Blood Stream Infection Testing Market?

The increasing prevalence of infectious diseases is expected to propel the growth of the blood stream infection testing market going forward. Infectious diseases are defined as illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites. Infectious disease rates are on the rise owing to several factors such as increased global travel, urbanization, climate change, antibiotic resistance, and gaps in vaccination coverage. Bloodstream infection testing is essential in infectious diseases for diagnosing and identifying pathogens causing sepsis and other severe infections, enabling targeted and effective treatment. For instance, in October 2024, according to the World Health Organization, a Switzerland-based international public health organization, approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, up from about 7.5 million in 2022, placing tuberculosis as the leading infectious disease killer. Therefore, the increasing prevalence of infectious diseases is driving the blood stream infection testing industry.

Key Players In The Global Blood Stream Infection Testing Market

Major companies operating in the blood stream infection testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, Siemens Healthcare Private Limited, Becton Dickinson and Company (BD), Grifols S.A., Hologic Inc., BIOMÉRIEUX SA, Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., DiaSorin S.p.A., Seegene Inc., Cepheid, Meridian Bioscience Inc., Biocartis NV, T2 Biosystems Inc., Molzym GmbH & Co. KG, Curetis GmbH, Accelerate Diagnostics Inc., OpGen Inc.

Global Blood Stream Infection Testing Market Trends and Insights

Major companies operating in the blood stream infection testing market are focusing on incorporating advanced technologies such as host-response diagnostics based on machine learning to enhance rapid detection, clinical decision support, and potential improvements in patient management. Host-response diagnostics analyze a patient’s immune system via gene expression signatures in blood samples using artificial intelligence (AI)-derived algorithms to infer infection presence, type, and likely severity in real time, helping clinicians make faster and more accurate treatment decisions. For instance, in January 2025, Inflammatix Inc., a US-based molecular diagnostics company, received clearance from the US Food and Drug Administration for TriVerity, a machine-learning-based molecular blood test designed to aid in the rapid evaluation of patients with suspected acute infections or sepsis, featuring measurement of 29 immune-related mRNAs and AI-generated scores indicating bacterial infection likelihood, viral infection likelihood, and risk of severe illness, with results intended to be available in roughly 30 minutes. TriVerity supports clinical decision making by reducing diagnostic uncertainty, assisting timely targeted therapy, and helping optimize hospital resource utilization when used alongside standard clinical evaluation and laboratory findings.

What Are Latest Mergers And Acquisitions In The Blood Stream Infection Testing Market?

In January 2023, Thermo Fisher Scientific Inc., a US-based life science and clinical research company, acquired Binding Site Group Ltd. for $2.8 billion. This acquisition aims to expand Thermo Fisher's specialty diagnostics segment by integrating The Binding Site's pioneering technologies for multiple myeloma diagnosis and monitoring, thereby enhancing clinical value, accelerating patient outcomes, and supporting advancements in the rapidly growing diagnostics market. The Binding Site Group Ltd. is a UK-based manufacturer of medical diagnostic products that focuses on the detection of cancer and immune disorders.

Regional Outlook

North America was the largest region in the blood stream infection testing market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Blood Stream Infection Testing Market?

The blood stream infection testing market consists of revenues earned by entities by providing services such as molecular diagnostics, serological assays, rapid diagnostic tests, next-generation sequencing, and pathogen identification and sensitivity testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The blood stream infection testing market also includes sales of blood culture media, molecular diagnostics kits, rapid diagnostic tests, automated blood culture systems, microbial identification panels, sepsis biomarker assays, and immunoassay kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Blood Stream Infection Testing Market Report 2026?

The blood stream infection testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the blood stream infection testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.